Please login to the form below

Not currently logged in
Email:
Password:

NICE revises Victoza recommendation

NICE has released a revised preliminary recommendation for Novo Nordisk's Victoza (liraglutide) for patients with type 2 diabetes

The National Institute for Health and Clinical Excellence (NICE) has released a revised preliminary recommendation on the use of Novo Nordisk's once-daily injectable human GLP-1 analogue Victoza (liraglutide) for patients with type 2 diabetes. The revised recommendation maintains the positioning issued in February 2010 and includes the recommendation that Victoza is a clinically and cost-effective treatment option under certain circumstances. 

These circumstances are that liraglutide 1.2mg daily is used in combination with one oral anti-diabetic tablet (metformin or a sulphonylurea) for treatment in patients with type 2 diabetes, if:

• they are intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and

• they are intolerant of thiazolidinediones and dipeptidyl peptidase-4 (DPP-4) inhibitors, or treatment with thiazolidinediones and DPP-4 inhibitors is contraindicated.

The release of the revised recommendation follows a second appraisal committee meeting held in April, and final guidance is expected by October this year. Novo Nordisk will continue dialogue with NICE regarding patient groups that could benefit from liraglutide 1.8mg and to support the use of liraglutide in line with the licence it was granted in June 2009 by the European Medicines Agency (EMA, formerly EMEA).

14th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics